Drug Profile

Human haemoglobin - Northfield Laboratories

Alternative Names: PolyHeme

Latest Information Update: 14 May 2009

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Northfield Laboratories
Class Haemoglobins; Plasma expanders
Mechanism of Action Haemoglobin stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Hypovolaemia

Most Recent Events

08 May 2009 Northfield Laboratories lays off substantially all of its operational and staff employees
01 May 2009 Northfield Laboratories receives complete response letter from the FDA for PolyHeme in Hypovolaemia
31 Dec 2008 PolyHeme receives priority review status for Hypovolaemia in the US

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com